Adagio Medical Submits Premarket Approval Application to FDA for vCLAS® Ventricular Ablation System for the Treatment of Ventricular Tachycardia

Stock Information for Adagio Medical Holdings Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Adagio Medical Holdings Inc

Adagio Medical Reports First Quarter 2026 Results and Meaningful Clinical Progress
Adagio Medical to Participate in the BofA Securities 2026 Health Care Conference
Adagio Medical Announces Positive Pivotal Results for vCLAS® Ventricular Ablation System
Adagio Medical's ULTA Technology to Be Featured at the Heart Rhythm 2026 Conference
Adagio Medical Receives IDE Approval from the FDA to Investigate Next-Generation vCLAS® Ventricular Ablation System
Adagio Medical to Participate in the 25th Annual Needham Virtual Conference
Adagio Medical Ultralow Temperature Ablation U.S. Pivotal Study Results to be Presented in Late-Breaking Session at Heart Rhythm Society 2026
Adagio Medical Reports Fourth Quarter and Full Year 2025 Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.